InvestorsHub Logo
Followers 52
Posts 9088
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Thursday, 12/21/2023 9:42:17 AM

Thursday, December 21, 2023 9:42:17 AM

Post# of 700032
-countdown -The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM). The application also requests to be considered under the MHRA's rapid 150-day review pathway, which the agency has established for new medicines for serious unmet medical needs.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News